Search Results - "Erba, Harry P"

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations by Lindsley, R. Coleman, Mar, Brenton G., Mazzola, Emanuele, Grauman, Peter V., Shareef, Sarah, Allen, Steven L., Pigneux, Arnaud, Wetzler, Meir, Stuart, Robert K., Erba, Harry P., Damon, Lloyd E., Powell, Bayard L., Lindeman, Neal, Steensma, David P., Wadleigh, Martha, DeAngelo, Daniel J., Neuberg, Donna, Stone, Richard M., Ebert, Benjamin L.

“…Acute myeloid leukemia (AML) can develop after an antecedent myeloid malignancy (secondary AML [s-AML]), after leukemogenic therapy (therapy-related AML…”
Get full text

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study by Perl, Alexander E, MD, Altman, Jessica K, MD, Cortes, Jorge, MD, Smith, Catherine, MD, Litzow, Mark, MD, Baer, Maria R, MD, Claxton, David, Prof, Erba, Harry P, Prof, Gill, Stan, PhD, Goldberg, Stuart, MD, Jurcic, Joseph G, Prof, Larson, Richard A, Prof, Liu, Chaofeng, PhD, Ritchie, Ellen, MD, Schiller, Gary, MD, Spira, Alexander I, MD, Strickland, Stephen A, MD, Tibes, Raoul, MD, Ustun, Celalettin, MD, Wang, Eunice S, Prof, Stuart, Robert, Prof, Röllig, Christoph, MD, Neubauer, Andreas, Prof, Martinelli, Giovanni, Prof, Bahceci, Erkut, MD, Levis, Mark, Dr

“…Summary Background Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall…”
Get full text

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study by Ustun, Celalettin, Le-Rademacher, Jennifer, Wang, Hai-Lin, Othus, Megan, Sun, Zhuoxin, Major, Brittny, Zhang, Mei-Jie, Storrick, Elizabeth, Lafky, Jacqueline M., Chow, Selina, Mrózek, Krzysztof, Attar, Eyal C., Nand, Such, Bloomfield, Clara D., Cripe, Larry D., Tallman, Martin S., Appelbaum, Frederick, Larson, Richard A., Marcucci, Guido, Roboz, Gail J., Uy, Geoffrey L., Stone, Richard M., Jatoi, Aminah, Shea, Thomas C., de Lima, Marcos, Foran, James M., Sandmaier, Brenda M., Litzow, Mark R., Erba, Harry P., Hurria, Arti, Weisdorf, Daniel J., Artz, Andrew S.

“…The preferred post-remission therapy for older patients with acute myeloid leukemia (AML) in first complete remission (CR1) remains uncertain. In this…”
Get full text

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia by Minagawa, Kentaro, Jamil, Muhammad O, Al-Obaidi, Mustafa, Pereboeva, Larisa, Salzman, Donna, Erba, Harry P, Lamb, Lawrence S, Bhatia, Ravi, Mineishi, Shin, Di Stasi, Antonio

“…Approximately fifty percent of patients with acute myeloid leukemia can be cured with current therapeutic strategies which include, standard dose chemotherapy…”
Get full text

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study by Ravandi, Farhad, Prof, Ritchie, Ellen K, MD, Sayar, Hamid, MD, Lancet, Jeffrey E, MD, Craig, Michael D, MD, Vey, Norbert, Prof, Strickland, Stephen A, MD, Schiller, Gary J, Prof, Jabbour, Elias, MD, Erba, Harry P, Prof, Pigneux, Arnaud, Prof, Horst, Heinz-August, Prof, Recher, Christian, Prof, Klimek, Virginia M, MD, Cortes, Jorge, Prof, Roboz, Gail J, MD, Odenike, Olatoyosi, MD, Thomas, Xavier, MD, Havelange, Violaine, MD, Maertens, Johan, Prof, Derigs, Hans-Günter, Prof, Heuser, Michael, MD, Damon, Lloyd, Prof, Powell, Bayard L, Prof, Gaidano, Gianluca, Prof, Carella, Angelo-Michele, MD, Wei, Andrew, MBBS, Hogge, Donna, Prof, Craig, Adam R, MD, Fox, Judith A, PhD, Ward, Renee, MD, Smith, Jennifer A, PhD, Acton, Gary, MD, Mehta, Cyrus, Prof, Stuart, Robert K, MD, Kantarjian, Hagop M, Prof

“…Summary Background Safe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukaemia. We investigated the…”
Get full text

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia by Dillon, Laura W, Higgins, Jake, Nasif, Hassan, Othus, Megan, Beppu, Lan, Smith, Thomas H, Schmidt, Elizabeth, Valentine Iii, Charles C, Salk, Jesse J, Wood, Brent L, Erba, Harry P, Radich, Jerald P, Hourigan, Christopher S

“…The presence of measurable residual disease (MRD) is strongly associated with treatment outcomes in acute myeloid leukemia (AML). Despite the correlation with…”
Get full text

Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data by Othus, Megan, Garcia-Manero, Guillermo, Godwin, John E, Weick, James K, Appelbaum, Frederick R, Erba, Harry P, Estey, Elihu H

“…We have previously shown that complete response (CR) rates and overall survival of patients with acute myeloid leukemia have improved since the 1980s. However,…”
Get full text

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network by Termini, Christina M, Moseley, Anna, Othus, Megan, Appelbaum, Frederick R, Chauncey, Thomas R, Erba, Harry P, Fang, Min, Lee, Stanley C, Naru, Jasmine, Pogosova-Agadjanyan, Era L, Radich, Jerald P, Willman, Cheryl L, Wu, Feinan, Meshinchi, Soheil, Stirewalt, Derek L

Get full text

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors by KANTARJIAN, Hagop M, ERBA, Harry P, PETERSDORF, Stephen, SHAMI, Paul J, YEAGER, Andrew M, ECKERT, Stephen, ABICHANDANI, Rekha, FADERL, Stefan, CLAXTON, David, ARELLANO, Martha, LYONS, Roger M, KOVASCOVICS, Tibor, GABRILOVE, Janice, CRAIG, Michael, DOUER, Dan, MARIS, Michael

“…This phase II study assessed clofarabine monotherapy in older adults (>or= 60 years of age) with untreated acute myeloid leukemia (AML) and at least one…”
Get full text

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial by JAIN, Nitin, CURRAN, Emily, POIRE, Xavier, KOVAL, Greg, SHANNON, Kevin, REDDY, Poluru L, JOSEPH, Loren, ATALLAH, Ehab L, DY, Philip, THOMAS, Sachdev P, SMITH, Scott E, DOYLE, L. Austin, IYENGAR, Neil M, STADLER, Walter M, LARSON, Richard A, STOCK, Wendy, ODENIKE, Olatoyosi, DIAZ-FLORES, Ernesto, KUNNAVAKKAM, Rangesh, POPPLEWELL, Leslie, KIRSCHBAUM, Mark H, KARRISON, Theodore, ERBA, Harry P, GREEN, Margaret

“…The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown…”
Get full text

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia by Erba, Harry P., Becker, Pamela S., Shami, Paul J., Grunwald, Michael R., Flesher, Donna L., Zhu, Min, Rasmussen, Erik, Henary, Haby A., Anderson, Abraham A., Wang, Eunice S.

“…This open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double…”
Get full text

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL by Ravandi, Farhad, Othus, Megan, O'Brien, Susan M., Forman, Stephen J., Ha, Chul S., Wong, Jeffrey Y.C., Tallman, Martin S., Paietta, Elisabeth, Racevskis, Janis, Uy, Geoffrey L., Horowitz, Mary, Takebe, Naoko, Little, Richard, Borate, Uma, Kebriaei, Partow, Kingsbury, Laura, Kantarjian, Hagop M., Radich, Jerald P., Erba, Harry P., Appelbaum, Frederick R.

“…This multicenter trial was conducted to determine whether the addition of dasatinib to chemotherapy followed by an allogeneic hematopoietic cell transplant…”
Get full text

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia by Medeiros, Bruno C, Othus, Megan, Fang, Min, Appelbaum, Frederick R, Erba, Harry P

“…Clonal heterogeneity is a hallmark of malignant transformation. In acute myeloid leukemia, acquired cytogenetic abnormalities are important independent…”
Get full text

Acute myeloid leukaemia by DiNardo, Courtney D, Erba, Harry P, Freeman, Sylvie D, Wei, Andrew H

“…Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific…”
Get full text

Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia by Minagawa, Kentaro, Jamil, Muhammad O, Al-Obaidi, Mustafa, Pereboeva, Larisa, Salzman, Donna, Erba, Harry P, Lamb, Lawrence S, Bhatia, Ravi, Mineishi, Shin, Di Stasi, Antonio

“…[This corrects the article DOI: 10.1371/journal.pone.0166891.]…”
Get full text

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report by Pogosova-Agadjanyan, Era L, Moseley, Anna, Othus, Megan, Appelbaum, Frederick R, Chauncey, Thomas R, Chen, I-Ming L, Erba, Harry P, Godwin, John E, Jenkins, Isaac C, Fang, Min, Huynh, Mike, Kopecky, Kenneth J, List, Alan F, Naru, Jasmine, Radich, Jerald P, Stevens, Emily, Willborg, Brooke E, Willman, Cheryl L, Wood, Brent L, Zhang, Qing, Meshinchi, Soheil, Stirewalt, Derek L

“…The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage…”
Get full text

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG by Walter, Roland B, Othus, Megan, Löwenberg, Bob, Ossenkoppele, Gert J, Petersdorf, Stephen H, Pabst, Thomas, Vekemans, Marie-Christiane, Appelbaum, Frederick R, Erba, Harry P, Estey, Elihu H

Get full text

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients by Pogosova-Agadjanyan, Era L, Hua, Xing, Othus, Megan, Appelbaum, Frederick R, Chauncey, Thomas R, Erba, Harry P, Fitzgibbon, Matthew P, Jenkins, Isaac C, Fang, Min, Lee, Stanley C, Moseley, Anna, Naru, Jasmine, Radich, Jerald P, Smith, Jenny L, Willborg, Brooke E, Willman, Cheryl L, Wu, Feinan, Meshinchi, Soheil, Stirewalt, Derek L

“…Studies have not systematically compared the ability to verify performance of prognostic transcripts in paired bulk mononuclear cells versus viable…”
Get full text

Has there been progress in the treatment of older patients with acute myeloid leukemia? by Erba, Harry P., MD, PhD

“…The treatment of older patients with acute myeloid leukemia (AML) has become increasingly important as the population ages. Progress, measured by overall…”
Get full text

Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy by Erba, Harry P

“…Highlights • No standard of care exists for older patients with newly diagnosed AML. • Prognosis for these patients with recommended low-intensity therapies is…”
Get full text